All News

Maintaining independence was found to the be the most common health care goal in patients with stage 4 neuroendocrine tumors, a recent survey found.

Initially, we used my husband's diagnosis to show our support as we navigated this journey and joined a new “club” we really didn’t want to be a part of.

One patient describes the management of symptoms of graft-versus-host disease as playing Whac-a-Mole and emphasizes the importance of awareness and education for both patients and their families.

Having cancer care denied or delayed is not a harmless situation when your life is on the line.

Going through cancer is a marathon, not a sprint.

As part of CURE®’s Heal at Home series, we offer a guide on ostomies following surgery and how patients can best care for their stomas.

Cynthia Chmielewski is a multiple myeloma hero for many around the world.

As a part of its “Speaking Out” video series, CURE® spoke with Meryl Uranga, on behalf of KidneyCAN, about the importance of working as a team with their clinicians and getting educated before making decisions.

I recently came across a Twitter thread where people were shaming a cancer survivor’s decisions, forcing me to step back before reacting.

There were some monumental FDA approvals in the cancer space during 2022 — here’s a roundup of our most-read agency decisions of the year.

From prostate cancer to disease spread in the brain, one patient learned how to recognize how far he has come since his journey began.

When cancer entered our life, fear was a constant. However, we tried to live as joyously as possible between check-ups.

He dreams that this ever-growing body of knowledge will progressively improve the ability to understand and treat cancer; multiple myeloma has been at the center of this dream.

While the large cancer hospitals do amazing work, I am extremely grateful for my local cancer center.

One expert explains how the road to cancer drug development isn’t a smooth one, but progress can be made nonetheless.

Data demonstrate that iberdomide alone or in combination with other treatments may be a promising option for patients with relapsed/refractory lymphoma.

Although triplet therapy may be effective and tolerable for patients with BRAF-mutant melanoma, each patient’s case should be considered before deciding if it is the right course of treatment, according to an expert.

Recent study results showed that patients with advanced HER2-positive breast cancer lived longer without disease progression when treated with Enhertu compared to when treated with Xeloda.

Imfinzi alone or combined with Imjudo may improve survival and tumor response when administered before surgery, opening the door to neoadjuvant mesothelioma treatments.

Some patients are at higher risk of infection, so it’s critical that they keep their care team up to date on any symptoms.

FDA-approved immunotherapies offer patients with metastatic or recurrent sarcomatoid RCC more treatment choices and improved outcomes.

After being diagnosed with cancer, my love for December is not just Christmas.

From investigative journalist, Drew Griffin’s cancer-related death to Jane Fonda’s lymphoma update, here’s what’s happening in the oncology space this week.

Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.

The past 20 years have brought great advances to advocacy groups, helping to improve patients’ quality of life. But more work is needed to raise awareness in underserved groups.

It is important that caregivers take care of not only the patient, but also themselves, as the diagnosis may affect their mental health.

No matter how grateful I feel this holiday season, I fear that my daughter’s no evidence of disease status was just a roll of the dice — and another roll can take us back to the world of cancer.

A childhood cancer survivor now works raising funds for Children’s Hospital of Philadelphia, the same hospital where she received treatment for Ewing sarcoma at 12 years old.

If approved by the FDA, zanidatamab could be the first HER-2 targeted therapy for patients with biliary tract cancers.

"We call ourselves the wolf pack. ... It is kind of tongue in cheek, but there is some seriousness behind how we view each other in terms of having each other’s backs,” said Trevor Maxwell, a stage 4 colon cancer survivor and the founder of Man Up to Cancer.